Praxis heads toward H2 2026 elsunersen readout in SCN2A epilepsy
EMBRAVE3 will test whether elsunersen cuts seizure frequency in infants with early-seizure-onset SCN2A DEE, a disease with no approved disease-modifying treatment.
Executive Summary
- Praxis Precision Medicines is advancing a registrational trial of its antisense drug elsunersen toward a readout that will show whether it reduces seizure frequency in infants with a severe, currently untreatable genetic epilepsy.
- The FDA agreed late last year to let the trial compare outcomes to patients' own seizure history rather than to a placebo group, reflecting the disease's severity and the mechanistic case for the drug, and setting a lower structural bar for what counts as a positive result.
- A modest reduction in the trial's enrollment target came alongside routine recruitment progress, not a sign of struggle, and the trial remains open and actively enrolling toward its guided readout window.
- This readout is one of several registrational catalysts Praxis has guided across its neuroscience pipeline this year, so its outcome will be read partly as a signal of the company's broader execution.
The trial
EMBRAVE3 (NCT07019922) is a Phase 3, registrational study of elsunersen in pediatric patients with a gain-of-function SCN2A variant and seizure onset before three months of age, with a primary endpoint set to assess the drug's effect on seizure frequency. The trial has recruited across sites in the United States, Brazil, Germany, and Italy since opening in August 2025. Enrollment criteria require at least four countable motor seizures per 28 days during a baseline observation period, establishing the within-patient comparator the endpoint will be measured against. NCT07019922A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The design shift
In December 2025, Praxis said it aligned with the FDA on the EMBRAVE3 design and converted it to a single-arm, baseline-controlled study, citing the high unmet need and mechanistic rationale for elsunersen. That structural choice means the readout will judge seizure reduction against each patient's own pretreatment seizure count rather than against a separate placebo arm, a lower bar than a randomized, controlled comparison but one the agency has already accepted for this population. PraxisPraxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of ProgressJan 12, 2026
Enrollment context
The trial's anticipated enrollment moved from 50 to 40 patients in a registry update logged May 27, 2026, a 20% reduction that sits at the routine threshold the operational model tracks and is flagged as typical for this trial design. The trial has logged three registry events since its June 2025 initial filing: the enrollment change, and an August 2025 status move to Recruiting from Not yet recruiting, with no amendments to the primary endpoint or primary completion date recorded. NCT07019922A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922
The guided window
Praxis said in its January 12, 2026 business-outlook release that topline EMBRAVE3 results are expected in the second half of 2026, alongside registrational readouts for two other pipeline drugs, vormatrigine and relutrigine. The trial's registry primary completion date is listed as June 1, 2026, ahead of the guided readout window, which is consistent with a trial completing enrollment before its sponsor discloses topline results. Praxis+1Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of ProgressJan 12, 2026A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922
The broader portfolio
Elsunersen sits inside a CNS pipeline where Praxis has already recorded relutrigine's Breakthrough Therapy Designation for SCN2A and SCN8A DEEs and a stopped-early interim analysis favoring relutrigine on efficacy grounds in a related indication. Elsunersen itself has received Orphan Drug and Rare Pediatric Disease designations from the FDA and Orphan Drug and PRIME designations from the European Medicines Agency, signaling regulatory recognition of the disease's severity and unmet need rather than a view on the drug's likelihood of working. No other trial shares elsunersen's SCN2A gene-expression target and mechanism in this indication; the only other Praxis SCN2A program in registry data, PRAX-222, is a small-molecule ion-channel modulator in Phase 1/2 rather than a direct comparator. Praxis+1Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of ProgressJan 12, 2026A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.